$2.32 Billion is the total value of HealthCor Management, L.P.'s 73 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CNC | New | CENTENE CORP DEL | $61,228,000 | – | 982,630 | +100.0% | 2.64% | – |
| JAZZ | New | JAZZ PHARMACEUTICALS PLC | $59,999,000 | – | 460,790 | +100.0% | 2.59% | – |
| CI | New | CIGNA CORP NEW | $42,390,000 | – | 211,780 | +100.0% | 1.83% | – |
| CANO | New | CANO HEALTH INC | $34,930,000 | – | 2,754,730 | +100.0% | 1.51% | – |
| BDX | New | BECTON DICKINSON & CO | $34,548,000 | – | 140,540 | +100.0% | 1.49% | – |
| FATE | New | FATE THERAPEUTICS INC | $7,613,000 | – | 128,450 | +100.0% | 0.33% | – |
| BNTX | New | BIONTECH SEsponsored ads | $6,467,000 | – | 23,690 | +100.0% | 0.28% | – |
| INCY | New | INCYTE CORP | $5,159,000 | – | 75,000 | +100.0% | 0.22% | – |
| New | ARYA SCIENCES ACQUISITN CORP | $4,940,000 | – | 500,000 | +100.0% | 0.21% | – | |
| LPTX | New | LEAP THERAPEUTICS INC | $4,812,000 | – | 1,200,000 | +100.0% | 0.21% | – |
| RCUS | New | ARCUS BIOSCIENCES INC | $2,443,000 | – | 70,050 | +100.0% | 0.10% | – |
| VCYT | New | VERACYTE INC | $2,306,000 | – | 49,640 | +100.0% | 0.10% | – |
| RVNC | New | REVANCE THERAPEUTICS INC | $2,271,000 | – | 81,500 | +100.0% | 0.10% | – |
| MRTX | New | MIRATI THERAPEUTICS INC | $1,750,000 | – | 9,890 | +100.0% | 0.08% | – |
| New | PROCEPT BIOROBOTICS CORP | $1,427,000 | – | 37,400 | +100.0% | 0.06% | – | |
| ALNY | New | ALNYLAM PHARMACEUTICALS INC | $1,418,000 | – | 7,510 | +100.0% | 0.06% | – |
| New | DICE THERAPEUTICS INC | $1,402,000 | – | 42,800 | +100.0% | 0.06% | – | |
| AVIR | New | ATEA PHARMACEUTICALS INC | $1,282,000 | – | 36,580 | +100.0% | 0.06% | – |
| JNJ | New | JOHNSON & JOHNSON | $1,176,000 | – | 7,280 | +100.0% | 0.05% | – |
| IMGN | New | IMMUNOGEN INC | $1,134,000 | – | 200,000 | +100.0% | 0.05% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| HCA HOLDINGS INC | 27 | Q1 2022 | 6.2% |
| ZIMMER HLDGS INC | 26 | Q2 2022 | 9.3% |
| DANAHER CORPORATION | 26 | Q3 2022 | 5.6% |
| NEUROCRINE BIOSCIENCES INC | 26 | Q4 2022 | 7.8% |
| UNITEDHEALTH GROUP INC | 24 | Q3 2022 | 6.4% |
| VERTEX PHARMACEUTICALS INC | 24 | Q3 2021 | 5.3% |
| HUMANA INC | 22 | Q3 2022 | 6.6% |
| BRISTOL-MYERS SQUIBB CO | 22 | Q3 2022 | 9.2% |
| BIOGEN INC | 21 | Q3 2022 | 8.5% |
| LABORATORY CORP AMER HLDGS | 20 | Q2 2020 | 8.3% |
View HealthCor Management, L.P.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CareView Communications Inc | May 26, 2023 | 186,970,000 | 32.0% |
| Research Alliance Corp. IISold out | February 14, 2023 | 0 | 0.0% |
| ARYA Sciences Acquisition Corp IVSold out | February 14, 2022 | 0 | 0.0% |
| Aurinia Pharmaceuticals Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| MADRIGAL PHARMACEUTICALS, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Medicus Sciences Acquisition Corp.Sold out | February 14, 2022 | 0 | 0.0% |
| Arcturus Therapeutics Holdings Inc.Sold out | February 12, 2021 | 0 | 0.0% |
| Intersect ENT, Inc.Sold out | February 12, 2021 | 0 | 0.0% |
| NEVRO CORP | February 12, 2021 | 156,046 | 0.5% |
| ViewRay, Inc.Sold out | February 12, 2021 | 0 | 0.0% |
View HealthCor Management, L.P.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2023-05-26 |
| 4 | 2023-05-26 |
| SC 13D/A | 2023-05-26 |
| 4 | 2023-04-04 |
| 4 | 2023-04-04 |
| SC 13D/A | 2023-04-03 |
| 13F-HR | 2023-02-15 |
| SC 13G/A | 2023-02-14 |
| 4 | 2023-01-04 |
| 4 | 2023-01-04 |
View HealthCor Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.